Therefore, S100A9 upregulation may increase NLRP3 activation by inducing VNN-1-mediated ROS release during pancreatic duct injury in AP, which verifies that S100A9 is a critical target for AP therapy. Here, S100A9 is linked to alkaline phosphatase measurement.